The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain
Abstract
Increasing evidence suggests that 5-HT1A receptors are involved in the pathophysiology and treatment of schizophrenia. This paper investigated 5-HT1A receptor mRNA expression and binding density in female rats treated with aripiprazole (2.25 mg/kg/day), olanzapine (1.5 mg/kg/day), haloperidol (0.3 mg/kg/day) or vehicle (control) orally 3 times/day for 1 or 12 weeks. Animals were sacrificed 48 hours after the last administration. Aripiprazole significantly increased 5-HT1A receptor binding density by 33% in the CA1 region of the hippocampus and by 21% in the medial posterodorsal nuclei of posterior amygdala (MeP) compared to the control group after 1 week of treatment. Olanzapine significantly decreased 5-HT1A receptor binding density by 17-22% in Layers I-IV of the cingulate cortex after 1 week of treatment. Neither of these antipsychotic drugs affected 5-HT1A receptor binding density after 12 weeks drug treatment. As expected, haloperidol treatment did not have any significant effect on 5-HT1A binding density after 1 or 12 weeks of treatment. 5-HT1A receptor mRNA expression was not altered by antipsychotic treatment in any brain region. The results indicate that aripiprazole and olanzapine have differential effects on 5-HT1A expression, which may contribute to their distinct profiles in improving negative symptoms and cognitive deficits in schizophrenia.
Aripiprazole and olanzapine may produce adaptation and desensitisation of 5-HT1A receptor expression after long term treatment.
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INTRODUCTION
Compared to typical antipsychotics, atypical antipsychotic drugs such as olanzapine and aripiprazole are superior in ameliorating negative symptoms and cognitive function deficits in schizophrenia patients Mamo, 2003, Keefe et al., 2006) . It has been proposed that the atypical properties of antipsychotics are mainly achieved through high serotonin 5-HT2A receptor and weak D2 receptor blockade (Meltzer, 1999) . However, 5-HT2A antagonism alone does not appear to be effective, as the 5-HT2A antagonist ritanserin showed no effect on symptom improvement of schizophrenia (Bantick et al., 2001) . Research into the mechanisms of atypical antipsychotic drugs has previously focused on the serotonin 5-HT2A subtype, however, increasing attention is now also being shifted to other serotonin receptor subtypes, such as 5-HT1A receptors. In fact, newly approved antipsychotic drug aripiprozale has a 5-HT1A receptor partial agonist property.
The 5-HT1A receptor belongs to the family of G-protein-coupled receptors. 5-HT1A receptors are expressed with a high density in the raphe nuclei, and in cortical and limbic areas, especially in the cerebral cortex and hippocampus (Barnes and Sharp, 1999) . Lower levels of 5-HT1A receptors are found in brain regions such as the amygdala and striatum (Hall et al., 1997) . In the raphe nuclei, 5-HT1A receptors are located on the serotoninergic cell body and dendrites and act as presynaptic autoreceptors. Studies have shown that 5-HT1A agonists inhibit serotonin release in the hippocampus through acting on the 5-HT1A autoreceptors (Sprouse and Aghajanian, 1988, Barnes and Sharp, 1999) . They also act as postsynaptic receptors on terminals of serotoninergic neurons. It is well known that the hippocampus is related to cognition, emotion, learning and memory (Vogt et al., 1992, Vizi and Kiss, 1998) . Previous studies have demonstrated that 5-HT1A receptors are involved in mood, cognition, attention and memory (Barnes and Sharp, 1999 , Sumiyoshi et al., 2000 , Sumiyoshi et al., 2007 ; therefore, 5-HT1A receptors may be an important target of atypical antipsychotic drugs.
Most of post-mortem studies have indicated that 5-HT1A receptor binding densities are increased in several neocortical areas, such as the prefrontal, and anterior and posterior cingulate cortices of schizophrenia patients (Hashimoto et al., 1991 , Joyce et al., 1993 , Burnet et al., 1996b , Sumiyoshi et al., 1996b .
However, a PET study showed that 5-HT1A receptor density is decreased in the amygdala of schizophrenia (Yasuno et al., 2004) . It should be noted that despite the seemingly discrepant results as to whether there is an increase or decrease in the number of 5-HT1A receptors in schizophrenia, an intensive study into the high affinity sites (or "G-protein coupled and functional" sites) of 5-HT1A receptors in the post-mortem prefrontal cortex showed that these high affinity state receptors are, in fact, increased by up to 80% (Sumiyoshi et al., 1996b) . These authors used several concentrations of radioactive ligands to labele 5-HT1A receptors, while other postmortem (Dean et al., 1999) and PET (Frankle et al., 2006 ) studies used only one concentration of radiolabeled ligands, which might not be sensitive enough to replicate the 5-HT1A receptor up-regulation in these brain regions, such as prefrontal areas. Furthermore, clozapine has been reported to down-regulate 5-HT1A receptors in most cortical areas (Ase et al., 1999) . This combined evidence suggests that 5-HT1A receptors are involved in schizophrenia and antipsychotic drug treatments, especially for functions involved with the neocortical areas. Further studies examining the effects of antipsychotic drugs on 5-HT1A receptors in animals are warranted to help clarify the role of 5-HT1A receptors in the etiology and treatment of schizophrenia.
Studies have shown that the atypical antipsychotic drugs aripiprazole, clozapine and olanzapine may increase dopamine release in the prefrontal cortex and the hippocampus, an effect which was significantly inhibited by WAY-100635, a selective 5-HT1A receptor antagonist (Kapur and Remington, 1996 , Ichikawa et al., 2001 , Li et al., 2004 . Another study found that atypical antipsychotics olanzapine, clozapine, and ziprasidone (but not typical antipsychotic drug haloperidol) enhanced dopamine release in the medial prefrontal cortex, however this effect was abolished in 5-HT1A knock-out mice (Diaz-Mataix et al., 2005) . These findings provide strong evidence to support the role of 5-HT1A receptors in the action of atypical antipsychotic drugs including those that do not show a direct in vitro affinity for these receptors (i.e. olanzapine), at least partly via increasing dopamine release in the prefrontal cortex and the hippocampus. These effects may partly explain how atypical antipsychotic drugs improve negative symptoms and cognitive deficits. However, there is evidence that aripiprazole and olanzapine may have differential effects on cognitive function in schizophrenia patients. For example, aripiprazole has a greater efficacy to improve verbal memory compared to olanzapine (Kern et al., 2006) . Therefore, it is important to examine whether there are differential effects between the two atypical antipsychotics on 5-HT1A receptor expression, especially in brain regions related to cognitive function such as the hippocampus.
Previous studies have demonstrated that antipsychotic drugs have different affinities for serotonin and dopamine receptors. Olanzapine has a high affinity for 5-HT2A receptors (Ki=4nM) and D2 receptors (Ki=11nM), but no significant affinity for 5-HT1A receptors (Ki>7100nM) (DeLeon et al., 2004) , but it still increased dopamine release in the prefrontal cortex and hippocampus. On the other hand, aripiprazole is a 5-HT1A receptor partial agonist, D2 receptor partial agonist and 5-HT2A receptor antagonist (Li et al., 2004) . It has a high affinity for 5-HT2A receptors (Ki=3.4nM), 5-HT1A receptors (Ki=4.4nM) and D2 receptors (Ki=0.45nM) (DeLeon et al., 2004) .
The typical antipsychotic drug, haloperidol, mainly possesses D2 receptor antagonist properties and has high affinity with D2 receptor (Ki=0.7nM). It has no significant affinity for 5HT1A or 5-HT2A receptors (DeLeon et al., 2004) and has no significant role in the improvement of negative symptoms and cognitive function. In this study, we aimed to determine (1) whether the level of 5-HT1A receptor mRNA and/or binding density would be altered after antipsychotic drug treatment; (2) if any observed 5-HT1A receptor changes are brain region specific.
EXPERIMENTAL PROCEDURES

Animals and antipsychotic treatment
Female Sprague Dawley rats weighing 220-250 grams were obtained from the Animal Resource Centre (Perth, WA, Australia). After arrival, in order to accurately measuring food and water intake, rats were housed 1 per cage under environmentally controlled conditions (temperature 22°C, light cycle from 0700 to 1900h and dark cycle from 1900 to 0700h), with ad libitum access to water and standard laboratory chow. To minimize the possible stress caused by individual housing, the rat cages were put placed next to each other in the same room, and therefore they can smell each other. Rats could also see each other through the cage cover. In addition, a PVC tube was placed in the cage for rat playing. After a 1-week familiarization period, they were treated with aripiprazole (2.25mg/kg/day, Otsuka, Japan), olanzapine (1.5mg/kg/day, Eli Lilly, USA), haloperidol (0.3mg/kg/day, Sigma, Australia), or vehicle. The daily dosage was divided into 3 equal amounts and all rats were treated 3 times a day (06:00, 14:00, 22:00 hours) orally with a specially prepared drug pellet as described previously (Huang et al., 2006a , Han et al., 2008c . Dosages used in this study are based on our previous study and literature, and have been shown to be pharmacologically and behaviourally effective (Arjona et al., 2004 , Huang et al., 2006a . These selected doses all share a D2 occupancy of approximately 70-80% in rats , Natesan et al., 2006 . We have shown previously that the doses of the drugs and treatment (at 3 times a day) used in this study affects central receptor systems relative to their pharmacological profiles (Huang et al., 2006b , Han et al., 2008a , Han et al., 2008b , Han et al., 2009 indicating the effectiveness of these treatments. The minimum number of rats per group was 12. All rats were sacrificed forty-eight hours after the last drug treatment. Five rat brains from each group were used to measure 5-HT1A receptor mRNA and protein expression. All experimental procedures were approved by the Animal Ethics Committee, University of Wollongong, Australia, and complied with the NHMRC Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7 th Edition, 2004).
Histology
All rats were sacrificed using carbon dioxide asphyxiation between 0700 and 0900h, in order to minimize the circadian-induced variation of mRNA expression. Brains were immediately removed after death and frozen in liquid nitrogen and then stored at -80°C until sectioning. Coronal brain sections (14 µm) were cut at -17°C with a cryostat, and thaw-mounted onto polysine-coated slides. Sections for in situ hybridization were fixed in ice-cold phosphate-buffer containing 4%
paraformaldehyde. Acetylation was carried out in 0.25% acetic anhydride in 0.1M triethanolamine buffer (pH 8.0) for 10 min. Sections were then dehydrated in ethanol and stored at -20°C until use.
In situ hybridization
The specific antisense hybridization probes for the 5-HT1A -receptor were 5'- 
Receptor autoradiography
5-HT1A receptor binding was performed based on that described previously (Khawaja, 1995 , Burnet et al., 1997 Tris-HCl (pH7.4) containing10µM pargyline (Sigma). Non-specific binding was determined by incubating consecutive sections exposed to 10µM 5-HT. All sections were washed for 2 min and then 3 min in ice-cold 50mM Tris-HCl buffer.
After a brief rinse in ice-cold distilled water, the slides were rapidly dried under a stream of cold air and exposed to Kodak BioMax MR films for 15 weeks. Films were then developed using standard procedures.
Quantification
As in our previous work (Huang et al., 2006a) , all films was analyzed by using a computer-assisted image analysis system, Multi-Analysis, connected to a GS-690
Imaging Densitometer (Bio-Rad, USA). The 5-HT1A receptor mRNA expressions and binding densities were quantified bilaterally in the brain areas from two Bregma levels: 1.20mm, -2.76mm (as indicated in Figure 1 ), which identification of neuroanatomical structures was according to a standard rat brain atlas (Paxinos and Watson, 1997) . 
Statistical analysis
The data were analysed statistically using the SPSS 15.0 program (SPSS, Chicago, IL). 5-HT1A receptor mRNA expression and binding density for each brain area were analysed by two-way ANOVA (drug × treatment duration) followed by a post-hoc Tukey-Kramer-HSD test.
RESULTS
5-HT1A receptor binding
5-HT1A receptor binding was widely distributed in the rat brain. High levels of 5-HT1A receptor binding density were observed in the lateral septal nucleus, cingulate cortex, and hippocampus. 5-HT1A receptor binding was also observed in the amygdala and ventromedial hypothalamic nucleus, but at lower levels (Fig 1) .
Cingulate cortex
5-HT1A binding sites showed a laminar distribution pattern in the cingulate cortex and two binding bands were observed (Fig 1) . The upper band corresponded to cortical layers I-II and the deeper band corresponded to cortical layers III-IV.
In the upper binding band of the cingulate cortex, there was a significant effect of 
Medial posterodorsal nuclei of posterior amygdala (MeP)
Significant effects of drug treatment on 5-HT1A binding density were also observed in the MeP [F(3,32) = 3.1, P =0.043]. However, there was no effect of treatment period [F(1,32) = 1.1, P=0.314] or interaction between the two factors [F(3,32) = 2.7, P =0.064]. Compared with the control group, 5-HT1A receptor binding density was significantly decreased following 1 week of aripiprazole treatment (+21%, P =0.022), although no difference was observed after 12 weeks of treatment (Fig 2) . Olanzapine and haloperidol did not significantly affect 5-HT1A binding density in this brain region.
High levels of 5-HT1A binding density were found in the lateral septal nucleus.
However, no significant differences of 5-HT1A binding density were found between the antipsychotic and control groups (Table 1 and 2).
5-HT1A receptor mRNA expressions
High levels of 5-HT1A receptor mRNA expression were observed in the lateral septal nucleus and hippocampus, and lower levels of 5-HT1A mRNA expression were found in the amygdala. Unlike 5-HT1A receptor binding density, 5-HT1A mRNA expression did not present a clear laminar distribution in the cingulate cortex. Also, a high level of expression of 5-HT1A mRNA was found in the ventromedial hypothalamic nucleus, while low level expression was observed in the cingulate cortex (Fig 3) . As shown in Table 3 and Table 4 , compared to the control group, 5-HT1A receptor mRNA expression was not significantly affected by any treatment of the three antipsychotic drugs. autoreceptors on the raphe nuclei, which might inhibit serotonin production and then reduce release on terminal projections. This might lead to an upregulation of postsynaptic 5-HT1A receptors (Sprouse and Aghajanian, 1988, Barnes and Sharp, 1999) . Therefore, aripiprazole might target at 5-HT1A autoreceptors in the raphe nuclei to inhibit serotonin production and in the hippocampus (CA1) and MeP to reduce serotonin release, which are the areas that showed changes in 5-HT1A binding density in this study.
DISCUSSION
It is not clear why aripiprazole altered 5-HT1A receptor binding density after short term (1 week) treatment only, but not long term (12 weeks) treatment. It may be the result of adaptation and desensitization of 5-HT1A receptors to aripiprazole. Previous studies have suggested that chronic administration of 5-HT1A receptor agonists results in desensitization of receptors in the median raphe nucleus (Kreiss and Lucki, 1997, Blier and Ward, 2003) .
The hippocampus and amygdala have been involved in the neuropathology of schizophrenia (Rajarethinam et al., 2001 ). For example, magnetic resonance imaging (MRI) studies have shown changes of hippocampal and amygdala size and shape in schizophrenia patients (Nelson et al., 1998 , Wright et al., 2000 , Csernansky et al., 2002 . Furthermore, a study indicated that the volumes of the hippocampus and amygdala had a significant inverse correlation with positive, and negative symptoms, and with thought disorder in schizophrenia (Rajarethinam et al., 2001) . A PET scan suggested lower 5-HT1A receptor binding density in amygdala in schizophrenia (Yasuno et al., 2004) . This study has shown that aripiprazole upregulates 5-HT1A receptor binding density in the hippocampus (CA1) and MeP (Fig1, Table 1 and Table   2 ), which may be how aripoprazole improves the cognitive dysfunction and negative symptoms of schizophrenia. As discussed in the Introduction, aripiprazole is more effective than olanzapine in improving verbal memory (Kern et al., 2006) . This may be relevant to the present results showing that aripiprazole, but not olanzapine, receptor has close interactions with the 5-HT2A receptor (Ichikawa et al., 2001 , Li et al., 2004 . Studies have also found neuropathalogical changes in the cingulate cortex in schizophrenia (Knable et al., 2002 , Zavitsanou et al., 2004 . Postmortem studies have shown a significant increase in 5-HT1A binding density in the cingulate cortex in schizophrenia . In the present study olanzapine reduced 5-HT1A receptor binding density in the cingulate cortex after 1 week of treatment, which may contribute to efficacy of olanzapine in improving cognitive deficits, at least after acute treatment. In fact, olanzapine has been reported to be associated with improvement in higher cognitive functions related to the frontal lobe, such as memory organization (Sumiyoshi et al., 2006) .
In this study, haloperidol had no affect on 5-HT1A receptor binding density or mRNA expression. This is not surprising, given that haloperidol has no significant affinity for 5-HT1A or 5-HT2A receptors (DeLeon et al., 2004) . This is consistent with the therapeutic profile of haloperidol, in which it mainly controls positive symptoms of schizophrenia through dopamine D2 receptor antagonism (Kapur and Mamo, 2003) .
In consistent to our results, a previous study found that 2-weeks treatment of haloperidol did not affect the expression of 5-HT1A receptor mRNA (Burnet et al., 1996a) . However, another study reported that three weeks treatment of haloperidol increased (+25%) 5-HT1A receptor density in the inner layers of the cingulate cortex but decreased (-15%) in the entorhinal region of male rats (Ase et al., 1999) . It was noticed that, differing from our study, Ase et al. study had a longer drug withdraw period after last drug treatment (72 vs 48 hours), higher dosage in different treatment methods (1mg/kg, once daily, i.p. vs 0.3mg/kg, three time per day, oral), and used male rats (Ase et al., 1999) . These methodological differences may explain why they have obtained different results.
Since the present study used female rats only, the estrous cycle could be a factor which influences 5-HT1A receptor levels. However, pre-experiments in our laboratory have shown that, under the rearing conditions used in this study, the estrous cycles of all female rats are synchronized (unpublished data). Our observation was supported by an early report that female rats can synchronise their estrous cycles when housed together (McClintock, 1978) , although another study has reported that female rats do not synchronise their estrous cycles (Schank, 2001) . However, even if there is asynchrony of the estrous cycles, the control and antipsychotic treatment groups would be considered to have had a similar proportion of rats at various stages of the estrous cycle randomly distributed within them. Furthermore, the standard deviation of the data within each group was quite small, showing there is little variation in 5-HT1A receptor expressions between the rats in the same groups.
Therefore, the estrous cycle has minimal effects on 5-HT1Areceptor expressions in this study.
Previous studies showed that serotonin system such as 5-HT1A, 5-HT2A receptors have been involved in food intake and body weight gain (Dryden et al., 1996 , Park et al., 1999 , López-Alonso et al., 2007 . These studies suggested that 5-HT1A agonist affected food intake in a function selective way. 5-HT1A agonist may cause hypophagic or hyperphagic effects by targeting 5-HT1A receptor in the dorsal and median raphe (as presynaptic receptor) or hypothalamus (as postsynaptic receptor) (Park et al., 1999 , López-Alonso et al., 2007 .
Among the three antipsychotics used in this study, only aripiprazole has significant affinity to 5-HT1A receptors (DeLeon et al., 2004) . However, our previous study using the same set of animals has found that aripiprazole did not affect significantly food intake and body weight gains compared to vehicle (Han et al., 2008) . In this study, the expression of 5-HT1A receptors was detected only in the VMH, but not in the PVN and Arc. In consistent, there is no significant difference in 5-HT1A receptor expression in the VMH between aripiprazole and vehicle groups in this study. In addition, combined with data from previous report (Han et al., 2008) , we were able to analyse the relationships between the 5-HT1A receptor expression in the VMH and body weight/food intake, but we found no significantly correlation with food intake (all r<0.315, P>0.10) and body weight gain (all r<0.2, P>0.40) . These results suggest that the property of 5-HT1A partial agonist of aripiprazole may not contribute to body weight gain and food intake changes, which is consistent with clinical observation that aripiprazole dose not lead significant body weight gain and increase of food intake (Han et al., 2008 , Nasrallah, 2008 .
In addition, our previous studies showed olanzapine can lead significant body weight gain and increase of food intake (Han et al., 2008) , although olanzapine has no significant affinity to 5-HT1A receptors. Our previous studies have suggested that the olanzapine-induced weight gain might be produced by its targeting at H1 and 5-HT2A receptors in the specific nuclei of hypothalamus, as well as striatum and limbic nuclei relevant to the regulation of energy and reward (Huang et al., 2006 , Han et al., 2008 .
Although aripiprazole also has high affinity with 5-HT2A receptors (DeLeon et al., 2004) , it does not cause body weight gain and food intake increase (Han et al., 2008) .
It is interested to further investigate whether aripiprazole affects expressions of 5-HT2A receptors.
It is worth noting that the antipsychotic drugs used in this study have a different halflife in the brain. For example, olanzapine has a half-life of 5.1 hours in the rat brain (Aravagiri et al., 1999) . Since rats were sacrificed 48 hours after the last drug treatment, we could not rule out that the olanzapine-induced changes in 5-HT1A
receptors is a possible drug withdrawal response observed 2 days after the last treatment in this study. However it is unlikely that this is the case for the observed changes in the aripiprazole group. It has been shown that aripiprazole has a long elimination half-life (60-70 hours) and exerts its effects on D2/D3 receptors for almost 1 week after the last dose in humans (Grunder et al., 2008) . Unfortunately, there is no data available on its half-life in rats. It is understandable that aripiprazole may have a different half-life in rats from that in humans, however, even assuming a 4-6 times faster half-life of aripiprazole in rats, it may still have effects one and half days after the last treatment in rats. Therefore, the changes in 5-HT1A receptor density observed in this study are most likely an aripiprazole treatment effect.
In conclusion, atypical antipsychotic drugs such as aripiprazole and olanzapine may achieve some of their acute effects via directly and indirectly targeting on 5-HT1A
receptors. However chronic use may result in adaptation and densensitization of 5-HT1A, which suggests that long term administration of these antipsychotic drugs is not associated with alterations in receptor binding or mRNA expression, indicating secondary compensation (either at the level of second messenger systems or changes in neurotransmitter levels). It may also be achieved through compensation within other neurotransmitter systems such as dopaminergic and muscarinic systems. 
